Comparison of MRI Sequences to Predict IDH Mutation Status in Gliomas Using Radiomics-Based Machine Learning
- PMID: 38672080
- PMCID: PMC11048271
- DOI: 10.3390/biomedicines12040725
Comparison of MRI Sequences to Predict IDH Mutation Status in Gliomas Using Radiomics-Based Machine Learning
Abstract
Objectives: Regarding the 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors, the isocitrate dehydrogenase (IDH) mutation status is one of the most important factors for CNS tumor classification. The aim of our study is to analyze which of the commonly used magnetic resonance imaging (MRI) sequences is best suited to obtain this information non-invasively using radiomics-based machine learning models. We developed machine learning models based on different MRI sequences and determined which of the MRI sequences analyzed yields the highest discriminatory power in predicting the IDH mutation status.
Material and methods: In our retrospective IRB-approved study, we used the MRI images of 106 patients with histologically confirmed gliomas. The MRI images were acquired using the T1 sequence with and without administration of a contrast agent, the T2 sequence, and the Fluid-Attenuated Inversion Recovery (FLAIR) sequence. To objectively compare performance in predicting the IDH mutation status as a function of the MRI sequence used, we included only patients in our study cohort for whom MRI images of all four sequences were available. Seventy-one of the patients had an IDH mutation, and the remaining 35 patients did not have an IDH mutation (IDH wild-type). For each of the four MRI sequences used, 107 radiomic features were extracted from the corresponding MRI images by hand-delineated regions of interest. Data partitioning into training data and independent test data was repeated 100 times to avoid random effects associated with the data partitioning. Feature preselection and subsequent model development were performed using Random Forest, Lasso regression, LDA, and Naïve Bayes. The performance of all models was determined with independent test data.
Results: Among the different approaches we examined, the T1-weighted contrast-enhanced sequence was found to be the most suitable for predicting IDH mutations status using radiomics-based machine learning models. Using contrast-enhanced T1-weighted MRI images, our seven-feature model developed with Lasso regression achieved a mean area under the curve (AUC) of 0.846, a mean accuracy of 0.792, a mean sensitivity of 0.847, and a mean specificity of 0.681. The administration of contrast agents resulted in a significant increase in the achieved discriminatory power.
Conclusions: Our analyses show that for the prediction of the IDH mutation status using radiomics-based machine learning models, among the MRI images acquired with the commonly used MRI sequences, the contrast-enhanced T1-weighted images are the most suitable.
Keywords: IDH mutation status; MRI; artificial intelligence; glioma; machine learning; neuroimaging; radiomics.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Comparison of MRI Sequences to Predict ATRX Status Using Radiomics-Based Machine Learning.Diagnostics (Basel). 2023 Jun 29;13(13):2216. doi: 10.3390/diagnostics13132216. Diagnostics (Basel). 2023. PMID: 37443610 Free PMC article.
-
Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.BMC Med Imaging. 2024 May 3;24(1):104. doi: 10.1186/s12880-024-01274-9. BMC Med Imaging. 2024. PMID: 38702613 Free PMC article.
-
Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.J Magn Reson Imaging. 2021 May;53(5):1399-1407. doi: 10.1002/jmri.27434. Epub 2020 Nov 12. J Magn Reson Imaging. 2021. PMID: 33179832
-
Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.Eur Radiol. 2020 Aug;30(8):4664-4674. doi: 10.1007/s00330-020-06717-9. Epub 2020 Mar 19. Eur Radiol. 2020. PMID: 32193643 Review.
-
Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review.AJNR Am J Neuroradiol. 2021 Jan;42(1):94-101. doi: 10.3174/ajnr.A6875. Epub 2020 Nov 26. AJNR Am J Neuroradiol. 2021. PMID: 33243896 Free PMC article.
Cited by
-
A novel approach for classifying patients with adrenal tumors based on decision support systems and artificial intelligence.Hormones (Athens). 2025 Jun 30. doi: 10.1007/s42000-025-00682-y. Online ahead of print. Hormones (Athens). 2025. PMID: 40586837
-
Detection of antibodies in suspected autoimmune encephalitis diseases using machine learning.Sci Rep. 2025 Mar 31;15(1):10998. doi: 10.1038/s41598-025-95815-z. Sci Rep. 2025. PMID: 40164743 Free PMC article.
-
-New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates.Cancer Imaging. 2024 Oct 7;24(1):133. doi: 10.1186/s40644-024-00769-6. Cancer Imaging. 2024. PMID: 39375809 Free PMC article. Review.
-
Completely non-invasive prediction of IDH mutation status based on preoperative native CT images.Sci Rep. 2024 Nov 5;14(1):26763. doi: 10.1038/s41598-024-77789-6. Sci Rep. 2024. PMID: 39501053 Free PMC article.
-
From pixels to prognosis: leveraging radiomics and machine learning to predict IDH1 genotype in gliomas.Neurosurg Rev. 2025 Apr 29;48(1):396. doi: 10.1007/s10143-025-03515-z. Neurosurg Rev. 2025. PMID: 40299088 Free PMC article.
References
-
- Nicholson J.G., Fine H.A. Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discov. 2021;11:575–590. doi: 10.1158/2159-8290.CD-20-1474. - DOI - PubMed
-
- Weller M., van den Bent M., Preusser M., Le Rhun E., Tonn J.C., Minniti G., Bendszus M., Balana C., Chinot O., Dirven L., et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 2021;18:170–186. doi: 10.1038/s41571-020-00447-z. - DOI - PMC - PubMed
-
- WHO Classification of Tumours Editorial Board . Central Nervous System Tumours. 5th ed. Volume 6. International Agency for Research on Cancer; Lyon, France: 2021. [(accessed on 2 October 2023)]. (WHO Classification of Tumours Series). Available online: https://publications.iarc.fr/601.
-
- Cancer Genome Atlas Research Network. Brat D.J., Verhaak R.G., Aldape K.D., Yung W.K., Salama S.R., Cooper L.A., Rheinbay E., Miller C.R., Vitucci M., et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 2015;372:2481–2498. doi: 10.1056/NEJMoa1402121. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources